ARRY-543 is currently entering Phase 2 development for solid tumors.
As per the terms of the agreement, ASLAN Pharma will provide funding and will also be responsible for the development of ARRY-543 through proof of concept for patents with gastric cancer, through a development program conducted in Asia.
ASLAN Pharma will identify a global partner for Phase 3 development and commercialization.
It will initiate phase 2 trials in gastric cancer and other tumor types.
Array CEO Robert Conway said their partnership with ASLAN provides a great opportunity to fund and advance the development of ARRY-543.
"ASLAN’s development strategy of leveraging Asia to conduct clinical development is particularly compelling for ARRY-543 due to the high prevalence of patients with gastric cancer in Asia," Conway said.